VOLUNTIS: Voluntis announces its results for the first half of 2021
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
VOLUNTIS: Voluntis announces the completion of the acquisition by Aptar of a majority stake in Voluntis at a price of EUR 8 70 per share
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
VOLUNTIS: Voluntis announces the execution of a Share Purchase Agreement between its reference shareholders and Aptar regarding the acquisition of a majority stake in Voluntis at a price of EUR 8 70 per share
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
VOLUNTIS: Voluntis receives CE Mark for new version of Oleena with expanded clinical intelligence
New version now authorized for marketing in the United States and the European Union
13
th regulatory clearance (worldwide) obtained by Voluntis for a digital therapeutic
Cambridge (USA), Paris (France), May 12, 2021, 8:00 a.m. CET - Voluntis (Euronext Growth Paris, Ticker: ALVTX - ISIN: FR0004183960), a leader in digital therapeutics, today announced that it has received the CE mark for a new version of Oleena featuring expanded clinical intelligence.
Oleena, digital therapeutic for people with cancer
Oleena is Voluntis proprietary digital therapeutic that supports patients in the self-management of their symptoms in combination with a wide range of cancer treatments, while allowing healthcare teams to remotely monitor the progress of the disease. It is based on the Theraxium platform developed by Voluntis, which also serves as the foundation for the digital therapeutics the com